(Q38668948)

5 September 2017

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases (English)

1 reference

5 September 2017

0 references

1 reference

Valeria Calsolaro

1

1 reference

PubMed ID

26666230

5 September 2017

Paul Edison

series ordinal

2

1 reference

5 September 2017

1 December 2015

1 reference

5 September 2017

1 reference

5 September 2017

29

1 reference

5 September 2017

12

1 reference

5 September 2017

1023-1039

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-015-0301-8

5 September 2017

0 references

cites work

Epidemiology of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

2012 Alzheimer's disease facts and figures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Alzheimer's disease is type 3 diabetes-evidence reviewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Endocrine Function and Glucose Metabolism in Patients with Parkinson's Disease and their Alteration byl-Dopa1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Identification of insulin in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Diabetes mellitus and the risk of dementia: The Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucose tolerance status and risk of dementia in the community: the Hisayama study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin neuroprotection and the mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

How does brain insulin resistance develop in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Neuronal insulin signal transduction mechanisms in diabetes phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Alzheimer's disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

GLP-1, the gut-brain, and brain-periphery axes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Mining incretin hormone pathways for novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Is brain amyloid production a cause or a result of dementia of the Alzheimer's type?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Aβ oligomer-induced synapse degeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Peripheral hyperinsulinemia promotes tau phosphorylation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin receptor mRNA in the substantia nigra in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin resistance impairs nigrostriatal dopamine function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Amyloid precursor protein expression is upregulated in adipocytes in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Mechanisms of cell signaling and inflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Parkinson's disease and enhanced inflammatory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Insulin has multiple antiamyloidogenic effects on human neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0301-8

Mitochondrial efficiency and insulin resistance

21 January 2018

1 reference

12 December 2020

Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes.

1 reference

12 December 2020

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study

1 reference

12 December 2020

Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?

1 reference

12 December 2020

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.

1 reference

12 December 2020

Insulin resistance in Alzheimer's disease

1 reference

12 December 2020

Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes

1 reference

12 December 2020

Progression and prognosis in Parkinson's disease

1 reference

12 December 2020

The global prevalence of dementia: a systematic review and metaanalysis

1 reference

12 December 2020

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

12 December 2020

Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa

1 reference

12 December 2020

Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease?

1 reference

12 December 2020

10.1007/S40263-015-0301-8

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26666230